And the company, which develops cellular therapies aimed at fighting solid tumors, plans to expand its 37-person team by about 30% this year. Carisma Therapeutics President and CEO Steven Kelly.

Carisma Therapeutics had already laid off 95% of its team earlier this year. Now, a Hail Mary merger proposal with another biotech has fallen through. The cell therapy macrophage biotech had just six ...

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) Pre-clinical results showed that the novel in vivo anti-GPC3 ...

PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing ...

Carisma Therapeutics plans to let go of 37% of staffers and drop one of two clinical assets in an effort to fuel the immunotherapy-focused biotech into the third quarter of 2025. The update, shared ...

PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly ...

Baird has downgraded Carisma Therapeutics (NASDAQ:CARM) to neutral from outperform, citing a lack of near-term catalysts. The investment firm noted that Carisma (NASDAQ:CARM) has decided to pivot from ...

Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock ...

“NextUp” is a weekly NextHealth PHL feature that highlights the local leaders, organizations and research shaping the Greater Philadelphia region’s life sciences ecosystem. Email qmuse@phillymag.com ...

The latest price target for CARISMA Therapeutics (OTCID:CARM) was reported by D. Boral Capital on August 8, 2025. The analyst firm set a price target for $1.00 expecting CARM to rise to within 12 ...